Background
Alzheimer’s disease, AD dementia, dementia, AD)
PATHOLOGY
Alzheimer’s disease (AD) dementia is the most common type of dementia worldwide, accounting for an estimated 60–80% of cases [AD, the underlying pathology causing AD dementia, is characterized by abnormalities in glutamatergic pathways related to Acetylcholinesterase inhibitors (AChEIs) are efficacious symptomatic treatments for mild-to-moderate AD dementia [BI 425809 is a novel potent and selective GlyT1 inhibitor [This phase II proof-of-clinical concept (PoCC) and dose-ranging study was performed to test the efficacy and safety of a range of doses of BI 425809 in patients with mild-to-moderate probable AD dementia.